Patents by Inventor Kenichiro Kosai
Kenichiro Kosai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10662441Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.Type: GrantFiled: July 25, 2018Date of Patent: May 26, 2020Assignee: KAGOSHIMA UNIVERSITYInventors: Kenichiro Kosai, Yuqing Wang
-
Publication number: 20180346929Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.Type: ApplicationFiled: July 25, 2018Publication date: December 6, 2018Applicant: KAGOSHIMA UNIVERSITYInventors: Kenichiro KOSAI, Yuqing WANG
-
Patent number: 8709812Abstract: It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. The drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.Type: GrantFiled: March 21, 2012Date of Patent: April 29, 2014Inventors: Kenichiro Kosai, Jyunichi Kamizono, Satoshi Nagano
-
Publication number: 20140023619Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.Type: ApplicationFiled: March 23, 2012Publication date: January 23, 2014Applicant: KAGOSHIMA UNIVERSITYInventors: Kenichiro Kosai, Yuqing Wang
-
Publication number: 20120230954Abstract: It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. The drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.Type: ApplicationFiled: March 21, 2012Publication date: September 13, 2012Inventors: Kenichiro Kosai, Jyunichi Kamizono, Satoshi Nagano
-
Patent number: 8142770Abstract: It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. This drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.Type: GrantFiled: May 23, 2005Date of Patent: March 27, 2012Inventors: Jyunichi Kamizono, Satoshi Nagano, Kenichiro Kosai
-
Patent number: 8034589Abstract: Provided is a method of preparing a proliferation-regulated recombinant adenoviral vector effectively, comprising preparing a proliferation-regulated vector plasmid by preparing a restriction enzyme-recognizing sequence in a vector plasmid having a proliferation-regulating unit and having an E1A region, a protein-coding region in a E1B region, a poly(A) signal sequence, and a recombinase-recognizing sequence in that order from upstream, by deleting an endogenous promoter in the E1A region or an endogenous promoter regulating expression of the protein-coding gene in one protein-coding region of the E1B region thereof and inserting the restriction enzyme-recognizing sequences in the deficient site, and introducing a promoter expressing specifically in a target organ in the restriction enzyme-recognizing sequence in the restriction enzyme-recognizing sequence; and additionally, integrating the proliferation-regulated vector plasmid into a vector plasmid having a adenoviral genome prepared by deleting the E1 regiType: GrantFiled: July 26, 2004Date of Patent: October 11, 2011Assignee: Nagoya Industrial Science Research InstituteInventors: Kenichiro Kosai, Satoshi Nagano
-
Patent number: 7803780Abstract: A drug for preventing or treating heart diseases which comprises an expression vector containing CD9 gene as the active ingredient. In the present invention, the term “heart diseases” means diseases causative of heart failure, ischemic heart diseases, cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases, mayocarditis, arrhythmia and diseases associated with cardiac hypertrophy and/or tachycardia. In the present invention, the expression vector is a viral vector or a non-viral vector. A method for preventing or treating heart diseases which comprises expressing the CD9 gene in the heart. In the present invention, the prevention or the treatment is carried out by a gene therapy of transferring the CD9 gene. In the gene therapy, use is made of a drug comprising an expression vector containing the CD9 gene as the active ingredient.Type: GrantFiled: December 24, 2004Date of Patent: September 28, 2010Assignee: Nagoya Industrial Science Research InstituteInventors: Kenichiro Kosai, Hiroaki Ushikoshi
-
Publication number: 20090181907Abstract: It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. This drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.Type: ApplicationFiled: May 23, 2005Publication date: July 16, 2009Inventors: Jyunichi Kamizono, Satoshi Nagano, Kenichiro Kosai
-
Publication number: 20070161584Abstract: A drug for preventing or treating heart diseases which comprises an expression vector containing CD9 gene as the active ingredient. In the present invention, the term “heart diseases” means diseases causative of heart failure, ischemic heart diseases, cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases, mayocarditis, arrhythmia and diseases associated with cardiac hypertrophy and/or tachycardia. In the present invention, the expression vector is a viral vector or a non-viral vector. A method for preventing or treating heart diseases which comprises expressing the CD9 gene in the heart. In the present invention, the prevention or the treatment is carried out by a gene therapy of transferring the CD9 gene. In the gene therapy, use is made of a drug comprising an expression vector containing the CD9 gene as the active ingredient.Type: ApplicationFiled: December 24, 2004Publication date: July 12, 2007Inventors: Kenichiro Kosai, Hiroaki Ushikoshi
-
Publication number: 20070036759Abstract: Provided is a method of preparing a proliferation-regulated recombinant adenoviral vector effectively, comprising preparing a proliferation-regulated vector plasmid by preparing a restriction enzyme-recognizing sequence in a vector plasmid having a proliferation-regulating unit and having an E1A region, a protein-coding region in a E1B region, a poly(A) signal sequence, and a recombinase-recognizing sequence in that order from upstream, by deleting an endogenous promoter in the E1A region or an endogenous promoter regulating expression of the protein-coding gene in one protein-coding region of the E1B region thereof and inserting the restriction enzyme-recognizing sequences in the deficient site, and introducing a promoter expressing specifically in a target organ in the restriction enzyme-recognizing sequence in the restriction enzyme-recognizing sequence; and additionally, integrating the proliferation-regulated vector plasmid into a vector plasmid having a adenoviral genome prepared by deleting the E1 regiType: ApplicationFiled: July 26, 2004Publication date: February 15, 2007Inventors: Kenichiro Kosai, Satoshi Nagano
-
Publication number: 20050208466Abstract: A method for selectively isolating or visualizing a target cell differentiated from an embryonic stem cell, which comprises transferring a first recombinant DNA in which a first promoter, a gene having recombinase recognition sequences on both ends, and a selective marker gene of a target cell differentiated from an embryonic stem cell are arranged in this order from a 5? side, and the first promoter makes the selective marker gene express, and a second recombinant DNA in which a second promoter specifically expressing in a target cell differentiated from an embryonic stem cell, and a recombinase-expressing gene are arranged in this order from a 5? side, respectively into an embryonic stem cell. A kit for isolation or visualization, which comprises the first vector for transferring a gene containing a first DNA and the second vector for transferring a gene containing a second DNA.Type: ApplicationFiled: June 13, 2003Publication date: September 22, 2005Applicant: Nagoya Industrial Science Research InstituteInventors: Kenichiro Kosai, Tomoyuki Takahashi